<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02528721</url>
  </required_header>
  <id_info>
    <org_study_id>DM2-HP-0715</org_study_id>
    <nct_id>NCT02528721</nct_id>
  </id_info>
  <brief_title>Exalenz Lab Mode System Compared to Biopsy for H.Pylori Detection</brief_title>
  <official_title>Clinical Validation Study to Evaluate Presence of H. Pylori With 13C-Urea Breath Test Using the BreathID® Hp Lab System Compared to Biopsy Results</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Exalenz Bioscience LTD.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Exalenz Bioscience LTD.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Exalenz Dual Mode BreathID® Hp System comprised of IDkit: Hp™ TWO and the Dual Mode
      BreathID® Hp test device will be used to perform a urea breath test in the initial diagnosis
      and post treatment monitoring of H.pylori infection in adult patients and its results will be
      compared to biopsy results.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients undergoing esophagogastroduodenoscopy (EGD) for initial diagnosis of H.pylori
      infection or post therapy confirmation of eradication will be eligible to participate in the
      trial. Two sets of biopsies will be taken: one set for histological analysis and one set for
      rapid urease test (RUT) analysis. The two results will be used as a gold standard composite
      score in determining the presence of H.pylori bacteria in the stomach. The Urea Breath Test
      (UBT) using the Exalenz Dual Mode BreathID Hp System will also be performed within a week of
      the biopsy. The outcome of the UBT will be compared to composite score of the biopsy and the
      accuracy of the UBT will be evaluated. The UBT will be performed using breath collection
      bags, where the subject will be asked to breathe into the bags before and after ingestion of
      the 13C-labelled urea.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity is Described as the Accuracy of the Breath Test in Detecting H.Pylori Infection Compared to Biopsy</measure>
    <time_frame>9 months</time_frame>
    <description>Sensitivity of urea breath test with Dual Mode Breath Hp System in accurately detecting presence of H.pylori infection as compared to composite biopsy result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Specificity as Described as the Accuracy of the Breath Test in Detecting Absence of H.Pylori Infection Compared to Biopsy</measure>
    <time_frame>9 months</time_frame>
    <description>Specificity of urea breath test with Dual Mode Breath Hp System in accurately detecting lack of presence of H.pylori infection as compared to composite biopsy result</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Agreement in Determining Presence or Absence of H.Pylori Infection Compared to Biopsy</measure>
    <time_frame>9 months</time_frame>
    <description>Overall Agreement of urea breath test with Dual Mode Breath Hp System in accurately detecting presence of H.pylori infection as compared to composite biopsy result</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">282</enrollment>
  <condition>Helicobacter Pylori Infection</condition>
  <arm_group>
    <arm_group_label>Initial Diagnosis Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with clinical indication for H.pylori infection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Post Therapy Subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Dual Mode BreathID Hp System</intervention_name>
    <description>The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
    <arm_group_label>Initial Diagnosis Subjects</arm_group_label>
    <arm_group_label>Post Therapy Subjects</arm_group_label>
    <other_name>Hp™ TWO</other_name>
    <other_name>Dual Mode BreathID® Hp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age.

          -  Have the ability and willingness to sign the Informed Consent Form.

          -  Present with clinical indication of H. pylori and a candidate for upper endoscopy

        For Initial Diagnosis arm:

        • Symptomatic patients naïve to H.pylori treatment in the past 18 months

        For Post-Therapy arm:

          -  Documented biopsy with positive outcome prior to eradication therapy (including method
             of determination)

          -  Documented eradication therapy within the past 6 months and completed at least 6 weeks
             prior to UBT

        Exclusion Criteria:

          -  Participation in other interventional trials.

               -  Antibiotics and/or Bismuth preparations within four (4) weeks prior to breath
                  test.

               -  PPI or H2 blockers within two (2) weeks prior to breath test.

               -  Pregnant or breastfeeding women.

               -  Allergy to test substrates.

               -  Patient did not fast for the hour prior to the UBT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Del Sol Research Management</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ventura Clinical Trials</name>
      <address>
        <city>Ventura</city>
        <state>California</state>
        <zip>93003</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clincal Research</name>
      <address>
        <city>Lafayette</city>
        <state>Colorado</state>
        <zip>80026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palmetto Research</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hope Clinical Research</name>
      <address>
        <city>Kissimmee</city>
        <state>Florida</state>
        <zip>34741</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Gastro Group</name>
      <address>
        <city>Chevy Chase</city>
        <state>Maryland</state>
        <zip>20815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gasrtrenetrology Associates of Western Michigan, West Michigan Clinical Research Center</name>
      <address>
        <city>Wyoming</city>
        <state>Michigan</state>
        <zip>49519</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Care</name>
      <address>
        <city>New Hyde Park</city>
        <state>New York</state>
        <zip>11040</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Great Lakes Medical Research</name>
      <address>
        <city>Willoughby</city>
        <state>Ohio</state>
        <zip>44094</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovative Clinical Research</name>
      <address>
        <city>Rapd City</city>
        <state>South Dakota</state>
        <zip>57701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Digestive Disease Center of South Texas, P.L.L.C</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Barzilai Medical center</name>
      <address>
        <city>Ashkelon</city>
        <zip>7830604</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Tzrifin</city>
        <zip>70300</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2015</study_first_submitted>
  <study_first_submitted_qc>August 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 19, 2015</study_first_posted>
  <results_first_submitted>November 16, 2016</results_first_submitted>
  <results_first_submitted_qc>January 12, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 3, 2017</results_first_posted>
  <last_update_submitted>January 12, 2017</last_update_submitted>
  <last_update_submitted_qc>January 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 3, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Helicobacter Infections</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Initial Diagnosis Subjects</title>
          <description>Patients with clinical indication for H.pylori infection
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
        </group>
        <group group_id="P2">
          <title>Post Therapy Subjects</title>
          <description>Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="203"/>
                <participants group_id="P2" count="79"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="196"/>
                <participants group_id="P2" count="76"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Initial Diagnosis Subjects</title>
          <description>Patients with clinical indication for H.pylori infection
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
        </group>
        <group group_id="B2">
          <title>Post Therapy Subjects</title>
          <description>Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="196"/>
            <count group_id="B2" value="76"/>
            <count group_id="B3" value="272"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48.5" spread="14.94"/>
                    <measurement group_id="B2" value="49.0" spread="15.53"/>
                    <measurement group_id="B3" value="48.64" spread="15.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="164"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="80"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="108"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Sensitivity is Described as the Accuracy of the Breath Test in Detecting H.Pylori Infection Compared to Biopsy</title>
        <description>Sensitivity of urea breath test with Dual Mode Breath Hp System in accurately detecting presence of H.pylori infection as compared to composite biopsy result</description>
        <time_frame>9 months</time_frame>
        <population>According to the FDA Guidelines, if there is a discrepancy between the histology and the rapid urease test results (&quot;composite reference standard&quot;), the subject is considered &quot;unevaluable&quot; and thus not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Diagnosis Subjects</title>
            <description>Patients with clinical indication for H.pylori infection
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
          </group>
          <group group_id="O2">
            <title>Post Therapy Subjects</title>
            <description>Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
          </group>
        </group_list>
        <measure>
          <title>Sensitivity is Described as the Accuracy of the Breath Test in Detecting H.Pylori Infection Compared to Biopsy</title>
          <description>Sensitivity of urea breath test with Dual Mode Breath Hp System in accurately detecting presence of H.pylori infection as compared to composite biopsy result</description>
          <population>According to the FDA Guidelines, if there is a discrepancy between the histology and the rapid urease test results (&quot;composite reference standard&quot;), the subject is considered &quot;unevaluable&quot; and thus not included in the analysis.</population>
          <units>Percent positive agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.32" lower_limit="95.18" upper_limit="99.65"/>
                    <measurement group_id="O2" value="98.53" lower_limit="92.08" upper_limit="99.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Specificity as Described as the Accuracy of the Breath Test in Detecting Absence of H.Pylori Infection Compared to Biopsy</title>
        <description>Specificity of urea breath test with Dual Mode Breath Hp System in accurately detecting lack of presence of H.pylori infection as compared to composite biopsy result</description>
        <time_frame>9 months</time_frame>
        <population>According to the FDA Guidelines, if there is a discrepancy between the histology and the rapid urease test results (&quot;composite reference standard&quot;), the subject is considered &quot;unevaluable&quot; and thus not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Diagnosis Subjects</title>
            <description>Patients with clinical indication for H.pylori infection
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
          </group>
          <group group_id="O2">
            <title>Post Therapy Subjects</title>
            <description>Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
          </group>
        </group_list>
        <measure>
          <title>Specificity as Described as the Accuracy of the Breath Test in Detecting Absence of H.Pylori Infection Compared to Biopsy</title>
          <description>Specificity of urea breath test with Dual Mode Breath Hp System in accurately detecting lack of presence of H.pylori infection as compared to composite biopsy result</description>
          <population>According to the FDA Guidelines, if there is a discrepancy between the histology and the rapid urease test results (&quot;composite reference standard&quot;), the subject is considered &quot;unevaluable&quot; and thus not included in the analysis.</population>
          <units>Percent negative agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="97.9" lower_limit="93.99" upper_limit="99.57"/>
                    <measurement group_id="O2" value="100" lower_limit="93.51" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Overall Agreement in Determining Presence or Absence of H.Pylori Infection Compared to Biopsy</title>
        <description>Overall Agreement of urea breath test with Dual Mode Breath Hp System in accurately detecting presence of H.pylori infection as compared to composite biopsy result</description>
        <time_frame>9 months</time_frame>
        <population>According to the FDA Guidelines, if there is a discrepancy between the histology and the rapid urease test results (&quot;composite reference standard&quot;), the subject is considered &quot;unevaluable&quot; and thus not included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Initial Diagnosis Subjects</title>
            <description>Patients with clinical indication for H.pylori infection
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
          </group>
          <group group_id="O2">
            <title>Post Therapy Subjects</title>
            <description>Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Agreement in Determining Presence or Absence of H.Pylori Infection Compared to Biopsy</title>
          <description>Overall Agreement of urea breath test with Dual Mode Breath Hp System in accurately detecting presence of H.pylori infection as compared to composite biopsy result</description>
          <population>According to the FDA Guidelines, if there is a discrepancy between the histology and the rapid urease test results (&quot;composite reference standard&quot;), the subject is considered &quot;unevaluable&quot; and thus not included in the analysis.</population>
          <units>Percent overall agreement</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="179"/>
                <count group_id="O2" value="68"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.33" lower_limit="95.21" upper_limit="99.65"/>
                    <measurement group_id="O2" value="100" lower_limit="94.72" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Initial Diagnosis Subjects</title>
          <description>Patients with clinical indication for H.pylori infection
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
        </group>
        <group group_id="E2">
          <title>Post Therapy Subjects</title>
          <description>Patients wishing to confirm eradication of initially diagnosed H.pylori infection that are after treatment within the last 6 months
Dual Mode BreathID Hp System: The Dual Mode Breath ID Hp System consists of breath collection bags, a 13C-labelled substrate (urea) and a breath analyzer device</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="203"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cyst</sub_title>
                <description>Cyst discovered on epiglottis during standard EGD procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <description>Gastric ulcer discovered during EGD procedure</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <description>Nausea experienced for two minutes after drinking test substrate</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="203"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="79"/>
              </event>
              <event>
                <sub_title>Lightheadedness</sub_title>
                <description>Lightheadedness due to fasting for standard EGD procedure</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="203"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="79"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>VP of Clinical Affairs</name_or_title>
      <organization>Exalenz Bioscience</organization>
      <phone>972-8-9737502</phone>
      <email>melinaa@exalenz.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

